Bepotastine Besilate Patent Expiration
Bepotastine Besilate was first introduced by Bausch And Lomb Inc
Bepotastine Besilate Patents
Given below is the list of patents protecting Bepotastine Besilate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bepreve | US8784789 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | Jan 13, 2025 | Bausch And Lomb Inc |
| Bepreve | US8877168 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul 30, 2023
(Expired) | Bausch And Lomb Inc |
| Bepreve | US6780877 | Acid addition salt of optically active piperidine compound and process for preparing the same |
Sep 19, 2019
(Expired) | Bausch And Lomb Inc |
Bepotastine Besilate's Family Patents
Explore Our Curated Drug Screens
Bepotastine Besilate Generic API Manufacturers
Several generic applications have been filed for Bepotastine Besilate. The first generic version for Bepotastine Besilate was by Apotex Inc and was approved on Mar 5, 2019. And the latest generic version is by Somerset Therapeutics Llc and was approved on Aug 14, 2024.
Given below is the list of companies who have filed for Bepotastine Besilate generic, along with the locations of their manufacturing plants worldwide.
1. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Apr 5, 2023 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
2. APOTEX
Apotex Inc has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 5, 2019 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
3. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 18, 2019 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
4. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Aug 14, 2024 |